Skip to main content

“The first quarter was very active for Pharming and importantly, it was the first full quarter in which we received all of the benefits of the acquisition of commercialization rights for RUCONEST® in North America from certain subsidiaries of Valeant Phar

- Dr Sijmen de Vries, Pharming’s CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline